United States: Agricultural Bioengineering: The Shifting Landscape

Advances in gene editing are quickly transforming agribusiness. What are these advances? How are they regulated? And what's on the horizon?

The field of bioengineering is rapidly evolving with new tools that allow for simple, efficient, and highly-specific DNA and RNA editing. For instance, CRISPR gene editing, which borrows from the natural defense system of bacteria to cut and alter DNA, has immense potential for use in a variety of agricultural and therapeutic contexts.

The application of these techniques to food and agriculture poses a unique challenge to both governmental agencies and the private actors subject to their oversight. Determining where modified plants and animals fit within the coordinated regulatory framework established between the various agencies is an ongoing task. In a regulatory landscape that is often overlapping and frequently subject to change, this article is designed to help navigate the complicated terrain.

Bioengineering in Agriculture

Economic growth, population dynamics, land availability, and volatile weather are all variables in an increasingly complex and interdependent global agriculture industry. The world's population is expected to grow to almost 10 billion by 2050,1 leading to an increase in agricultural demand by roughly fifty percent compared to 2013 levels.2 As consumption continues on an upward trajectory in the coming decades, bioengineering has become a major factor in the growth and sustainability of global food supplies.3

There is ample activity in a number of arenas of bioengineering in agriculture, but CRISPR is leading the way and generating the most headlines. It has been used in a host of applications such as boosting crop resistance and protecting against disease in livestock.4 This is not to say that CRISPR is the only mechanism for bioengineering in agriculture; some companies are focusing on alternative techniques,5 such as recombinant DNA (rDNA), zinc finger nucleases (ZFN), and transcription activator-like effector nucleases (TALENs).

The market for genetically engineered products was worth almost $2 billion in 2014 and is expected to double by 2019.6 Despite continued calls for improved and updated oversight, regulation, and ethical accountability, some have declared it "open season" in gene editing of plants and animals.7,8

Regulatory Background and Overview

Spurred by developments in recombinant DNA in the 1980s, the White House Office of Science and Technology Policy (OSTP) issued the "Coordinated Framework for the Regulation of Biotechnology" (hereinafter "Coordinated Framework") on June 26, 1986.9 The Coordinated Framework was designed to outline a Federal regulatory policy for ensuring the safety of biotechnology products.10 Under the Framework, Congress charged three Federal agencies with spearheading the implementation of an array of laws11: the Environmental Protection Agency (EPA), the U.S. Department of Agriculture (USDA), and the Food and Drug Administration (FDA).

EPA's primary mission is to protect human health and the environment. In pursuing that goal, EPA's statutory authority in the biotechnology space stems largely from the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), the Federal, Food, Drug, and Cosmetics Act (FDCA) and the Toxic Substances Control Act (TSCA). Under FIFRA, EPA regulates pesticides, under the FDCA EPA established the amount of pesticide chemical residues that may be present in food, and under the TSCA EPA regulates biotechnology products that are new organisms not specifically excluded by the statute.12

EPA regulation of bioengineered products is largely focused on plant products which incorporate pesticide substances and toxic materials. To the extent that newly bioengineered products incorporate such pesticides and toxic materials, EPA may assess the safety of dietary exposures to residues of these substances in human or animal feed. For instance, if a genetically engineered (GE) CRISPR crop is altered to create its own pesticide, that would trigger EPA oversight.13

USDA focuses on agriculture and, for biotechnology purposes, this mostly relates to plant health and safety. The Animal and Plant Health Inspection Service (APHIS), an agency within USDA, has the general authority to regulate the importation, interstate movement, and environmental release of plants that pose a plant pest risk and animals used in feed that pose a health risk to livestock. A bioengineered organism is deemed a "regulated article" by APHIS if it is engineered using a donor organism, recipient organism, or a vector or vector agent.

FDA is largely tasked with keeping genetically engineered foods safe. Human and animal foods (including dietary supplements), cosmetics, human and veterinary drugs, human biological products and medical devices are just some of the categories of goods that fall under the ambit of FDA's regulations. FDA draws much of its authority from the Federal Food, Drug, and Cosmetic Act (FDCA) to ensure that foods offered to consumers, including those developed using genome editing techniques, are in compliance with legal requirements.

Recent Developments

OSTP updated the 1986 Coordinated Framework in 1992, making relatively minor adjustments that remained mostly unchanged until July 2015. In the intervening years, many large biotechnology breakthroughs occurred that have left the Coordinated Framework outdated and found the OSTP and the three designated agencies playing catch up.14

Due to the substantial advancements in the gene editing field, the Obama administration's Executive Office of the President (EOP) issued a memorandum,15 on July 2, 2015, to the three government agencies to update the Coordinated Framework. Their task was to clarify current roles and responsibilities, with the stated goal of preventing unnecessary barriers to future innovation. In response to EOP's request, the National Academies of Science produced an "Update to the Coordinated Framework,"16 released in January 2017. While the Update is comprehensive in its discussion of the statutory basis for regulating biotechnology, it does little to modernize the framework or discuss how to regulate emerging technologies, such as CRISPR.17

In the absence of needed adjustments to the Coordinated Framework, FDA, USDA and EPA have each taken a different tack on how to proceed in response to the gaps in regulation. In January 2017, FDA published draft guidance18 on regulating intentionally altered genomic DNA in animals, as well as guidance on gene-edited foods and mosquitoes.

FDA regulates bioengineered animals as "new animal drugs" since the modifications are intended for use in diagnosis, cure, mitigation, or treatment of animal diseases and/or affect the structure or function of the animals.19 The draft guidance indicated that the safety and efficacy of genetically edited animals would need to be demonstrated in a new animal drug application (NADA) submission. The guidance raised some eyebrows in the bioengineering field because it discussed making the trigger for regulation whether the GE animal was intended to be made, rather than the specific attributes of the GE animal or its manufacturing process.20

The period for comment on the draft guidance ended, however, and the results of the final guidance did not issue. As of April 2018, according to an FDA spokesperson, the agency is considering new public comments on whether gene-edited plants and foods pose added risks, but they have not provided any timeline for new policies.21

On July 29, 2016, Congress amended the Agricultural Marketing Act of 1947 to establish a National Bioengineered Food Disclosure Standard.22 The amendment gave USDA's Agricultural Marketing Service (AMS) two years to establish the standard and procedures for its implementation.

With the two year deadline fast approaching, AMS recently issued a proposed rule which was open to public comment until July 3, 2018.23 The proposed rule includes24:

  • Suggested uses of the term "bioengineering" (BE) or "BE foods" instead of GMO
  • Request for comments on two alternate definitions of BE food, the first requiring that any food derived from BE material is subject to disclosure requirements, and the second narrowing the meaning to only those foods containing "genetic material"
  • Lists of bioengineered commodities (both highly adopted and non-highly adopted)
  • Different options as to the parameters of a BE disclosure statement, including a one-sentence label, a standardized icon, a QR code or digital marker, and separate options for small food manufacturers
  • Three suggested thresholds for bioengineered food content that could necessitate disclosure
  • Record keeping procedures
  • A discussion of AMS's enforcement power
  • Compliance deadlines, currently set at January 1, 2020, for large companies and a year later for small companies (those with less than $10 million in annual receipts)

Since this proposed rule is not yet finalized, the list above is still subject to change.

In tandem with the proposed rule, USDA has been steadily approving more CRISPR edited crops. In April 2016, USDA announced that it would forego regulation of a CRISPR edited mushroom altered to resist browning.25 Not long after, it made a similar announcement regarding CRISPR edited corn created by DuPont.26 In September 2017, USDA greenlit an oilseed crop altered with CRISPR to produce enhanced omega-3 oil. The unifying logic in the recent spate of approvals is that, although these crops are certainly gene-edited, they are not genetically "modified," since they do not include foreign DNA.27

In a formal statement in March 2018, Secretary of Agriculture, Sonny Perdue, confirmed and clarified USDA's trend of allowing plant gene editing, saying that USDA "does not regulate or have any plans to regulate plants that could otherwise have been developed through traditional breeding techniques, as long as they are not plant pests or developed using plant pests."28 This implies that as long as a genetic alteration could have been bred in a plant – for example, a deletion, a base pair swap, or insertion – the plant will not be regulated, including CRISPR edited crops.29 His statement has led to speculation that a number of recently approved crops could reach supermarket shelves much quicker than originally anticipated.30, 31

There are important developments and rulings occurring outside the United States as well. As of this writing, the European Court of Justice is set to issue a preliminary opinion on whether New Plant Breeding Techniques (NPBT), like CRISPR, should fall under the European Union's laws on genetically modified organisms.32 Europe generally has fairly stringent laws on the regulation of GMO foods. But the European Court of Justice's opinion may soon more closely resemble rulings in the United States, where foods whose genomes have been edited without introducing foreign DNA from an another organism are given more leeway as compared to other recombinant products and foods.33

The Path Ahead

The multi-pronged approach to regulation of bioengineered products established by EPA, FDA, and USDA's Coordinated Regulatory Framework is still evolving and in flux. Efforts to develop and commercialize bioengineered foods will require careful scrutiny and attention to the changing regulations surrounding these products. With aforementioned FDA and USDA guidance in the works, but not yet finalized, and proposed rule changes frequently withdrawn, the regulatory landscape for genetically engineered foods and animals is rapidly recalibrating.

As circumstances fluctuate and technologies evolve, it is necessary to have counsel dedicated to monitoring regulatory changes and approval standards. After all, "open season" in agricultural bioengineering can shift quickly.


1 Food and Agriculture Organization, United Nations, The Future of Food and Agriculture (2017).

2 Id. at x.

3 Jennifer Kahn, The Crispr Quandary, N.Y. Times, Nov. 9, 2015, at MM63 (Sunday Magazine, headline in print as "Life Edited").

4 Id.

5 Brooke Borel, CRISPR, Microbes and More Are Joining the War Against Crop Killers, Nature, 543, 302-304, March 16, 2017.

6 Kahn, supra note 3.

7 Amy Harmon, Open Season is Seen in Gene Editing of Animals, N.Y. Times, Nov. 26, 2015, at A1..

8 Kahn, supra note 3.

9 Proposal for a Coordinated Framework for Regulation of Biotechnology, 49 Fed. Reg. 50856 (December 31, 1984). See also, Modernizing the Regulatory System for Biotechnology Products: Final Version of the 2017 Update to the Coordinated Framework for the Regulation of Biotechnology, at 4, fn. 8. ("The Federal Government recognized that a number of agencies, in addition to the EPA, FDA, and USDA, might have laws, regulations or guidelines that might be applicable to biotechnology products at some point in research, development, marketing, shipment, use, or disposal. The 1984 Proposal provided a matrix describing all the laws, regulations or guidelines that could potentially play a role. In addition to those agencies generally recognized as part of the Coordinated Framework, the matrix referenced Federal entities such as the Council on Environmental Quality, the U.S. Department of the Interior and the National Marine Fisheries Service. The Proposal noted that the matrix would be updated as appropriate, indicating that the Coordinated Framework was to be flexible in terms of which agencies might play a role in the regulation of biotechnology.")

10 Modernizing the Regulatory System for Biotechnology Products: Final Version of the 2017 Update to the Coordinated Framework for the Regulation of Biotechnology, Executive Office of the President, at 2 (January 2017), available at https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GEPlants/UCM537311.pdf

11 Id. at 3.

12 Id. at 10.

13 Brooke Borel, The U.S. Regulations for Biotechnology are Woefully Out of Date, Slate, April 21, 2017, available at http://www.slate.com/articles/technology/future_tense/2017/04/u_s_biotechnology_regulations_are_woefully_out_of_date.html.

14 Brooke Borel, The U.S. Regulations for Biotechnology are Woefully Out of Date, Slate, April 21, 2017, available at http://www.slate.com/articles/technology/future_tense/2017/04/u_s_biotechnology_regulations_are_woefully_out_of_date.html.

15 John P. Holdren, et al. Memorandum for Heads of Food and Drug Administration, Environmental Protection Agency, and Department of Agriculture, Off. of Sci. and Tech. Pol'y, July 2, 2015.

16 Modernizing the Regulatory System for Biotechnology Products, supra note 26.

17 Ryan Cross, White House Attempts to Clarify, But Not Change, Genetic Engineering Regulations, Chemical & Engineering Mag.,, American Chemical Society, Jan. 9, 2017, available at https://cen.acs.org/articles/95/web/2017/01/White-House-attempts-clarify-change.html?type=paidArticleContent.

18 Guidance for Industry: Regulation of Intentionally Altered Genomic DNA in Animals, Draft Guidance #187, Food and Drug Admin., Jan. 2017, available at https://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM113903.pdf.

19 See, e.g., FDA's approval for AquAdvantage Salmon, available at https://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/GeneticEngineering/GeneticallyEngineeredAnimals/ucm280853.htm.

20 Amy Maxmen, Gene-edited Animals Face US Regulatory Crackdown: Last-minute Proposal from Obama Administration Addresses CRISPR and Other Cutting-edge Technologies, Nature, Jan. 19, 2017, available at https://www.nature.com/news/gene-edited-animals-face-us-regulatory-crackdown-1.21331.

21 Megan Molteni, CRISPR'D Food, Coming Soon to a Supermarket Near You, WIRED, March 30, 2018, available at https://www.wired.com/story/crisprd-food-coming-soon-to-a-supermarket-near-you/.

22 Riette Van Laack, AMS's Proposal for BE (Bioengineered) Labeling; A Number of Questions Remain, Hyman, Phelps, & McNamara PC: FDA Law Blog, May 25, 2018, available at http://www.fdalawblog.net/2018/05/amss-proposal-for-be-bioengineered-labeling-a-number-of-questions-remain/.

23 Id.

24 Id.

25 Maxmen, supra note 20.

26 Erin Brodwin, The Next Generation of GMO Food is Here, and It's Technically Not a GMO, Bus. Insider (April 18, 2016), http://www.businessinsider.com/dupont-crispr-corn-in-stores-in-5-years#pq=nfDL8l.

27 Kristen V. Brown, Why CRISPR-Edited Food May Be in Supermarkets Sooner than you Think, Gizmodo, Jan. 16, 2018.

28 Secretary Perdue Issues USDA Statement on Plant Breeding Innovation, USDA, Press Release, March 28, 2018, available at https://www.usda.gov/media/press-releases/2018/03/28/secretary-perdue-issues-usda-statement-plant-breeding-innovation.

29 Megan Molteni, CRISPR'D Food, Coming Soon to a Supermarket Near You, WIRED, March 30, 2018, available at https://www.wired.com/story/crisprd-food-coming-soon-to-a-supermarket-near-you/.

30 Kristen V. Brown, Why CRISPR-Edited Food May Be in Supermarkets Sooner than you Think, Gizmodo, Jan. 16, 2018.

31 Katherine Ellen Foley, The USDA Says Crispr-Edited Foods Are Just As Safe As Ones Bred The Old-Fashioned Way, QUARTZ, April 2, 2018, available at https://qz.com/1242882/the-usda-drops-all-regulation-for-crispr-edited-crops/.

32 Simon Marks, EU Braces for Landmark Decision on Whether CRISPR, Other New Plant Breeding Techniques Will be Regulated as GMOs, Politico, January 18, 2018.

33 Id.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions